In my last article I summarized my discussions with DelMar Pharmaceuticals’ (Nasdaq: DMPI) President and CEO Saiid Zarrabian and the value proposition DelMar offers investors. To recap, DelMar … [Read more...] about DelMar Pharmaceuticals (Nasdaq: DMPI) Approaches a Key Inflection Point At the 2019 Society for Neuro-Oncology Annual Meeting
stock market
Foamix Pharmaceuticals: A dermatology play with more than 100% upside potential
Foamix Pharmaceuticals (NASDAQ: FOMX) shares have been on a free fall for the past six months, declining by more than 30 percent to $2.3. The clinical-stage company which develops and commercializes … [Read more...] about Foamix Pharmaceuticals: A dermatology play with more than 100% upside potential
MS Conference Call Exclusive: Reflecting on the 1st Half of 2019
Now that we are in the heat of summer the books have closed for the first half of the year. Here in the exclusive piece for our subscribers in which our team will individually reflect on our first … [Read more...] about MS Conference Call Exclusive: Reflecting on the 1st Half of 2019
Biopharma Stock Watch July 1st-4th
It suffices to say Q2 2019 (April-June) has been a wild ride. In 1Q19 the market bounced back with a vengeance from its low-point in December 2018 when it appeared the U.S and China were on the cusp … [Read more...] about Biopharma Stock Watch July 1st-4th
Evolus: A Performance Beauty Company “Built to Grow Overnight”: Part 2
To recap, in part 1 we talked about Evolus (Nasdaq: EOLS), a relatively young company (no pun intended) entering the medical aesthetics market. Their first product Jeuveau was approved by FDA in … [Read more...] about Evolus: A Performance Beauty Company “Built to Grow Overnight”: Part 2
Biopharma Stock Watch June 17th-21st
MS Performance Tracker Showing Data From Friday June 14th After The Market Closed Two weeks into June the markets are continuing to recover from the painful volatility we experienced in April and … [Read more...] about Biopharma Stock Watch June 17th-21st
My #1 Mid-Cap Biotech Stock Pick For 2019
The four qualities that I assign the most weight when evaluating a biotech company for viability is 1) An efficacious product 2) Sufficient funding 3) Competent leadership and 4) Relationships with … [Read more...] about My #1 Mid-Cap Biotech Stock Pick For 2019
Biopharma Stock Watch June 3rd-7th
May 27th-31st we saw a continuation of brutal market volatility spurred by an escalating trade war with china, new tariffs, and rhetoric of war with Iran. Trade negotiations earlier this month ended … [Read more...] about Biopharma Stock Watch June 3rd-7th
Portfolio Update: ADMA Biologics
The past two months have been eventful for my number one stock pick ADMA Biologics (Nasdaq: ADMA). Moreover, on Friday May 24th, 2019 I added a new stock to the MS portfolio- Regenxbio (Nasdaq: RGNX). … [Read more...] about Portfolio Update: ADMA Biologics
Biopharma Stock Watch May 27th-31st
A popular idea floating around the biotech community is that healthcare companies are insulated, or more so at least than other sectors, from a trade war with China. From a fundamental perspective, … [Read more...] about Biopharma Stock Watch May 27th-31st
You must be logged in to post a comment.